LTR Pharma (ASX:LTP) received ethics committee approval for a clinical study to evaluate its Oroflow intranasal spray in patients with oesophageal motility disorders, which impede the food swallowing function, according to a Wednesday filing with the Australian bourse.

The company expects to initiate the study in the coming quarter to assess Oroflow's effect in healthy volunteers before progressing to patients with the disorders.

"As a non-invasive intranasal spray, Oroflow may be particularly suited to patients with swallowing difficulties, removing the need to take an oral tablet while offering a rapid route of administration," the company said.